A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Aug 2017 Planned End Date changed from 6 Jan 2018 to 31 Jan 2018.
- 08 Aug 2017 Planned primary completion date changed from 6 Jan 2018 to 1 Jan 2018.
- 08 Aug 2017 Status changed from suspended to active, no longer recruiting.